Skip to main content
. 2022 Sep 12;12:15299. doi: 10.1038/s41598-022-17808-6

Table 2.

Linear mixed models presenting changes of the composite cognitive score according to urate-lowering therapies administration among community-dwelling older adults.

Time Estimated change from baseline Estimated differences in change from baseline Estimated differences in change from baseline
PNT mean [95%CI] p-value PT < 75% mean [95%CI] p-value PT ≥ 75% mean [95%CI] p-value PT < 75% vs PNT mean [95%CI] p-value PT ≥ 75% vs PNT mean [95%CI] p-value PT < 75% vs PNT mean [95%CI] p-value PT ≥ 75% vs PNT mean [95%CI] p-value
Not adjusted Adjusted(1)
3 years

− 0.060

[− 0.090 to − 0.029]

p = 0.0002

− 0.049

[− 0.251 to 0.153]

p = 0.633

0.055

[− 0.115 to 0.224]

p = 0.528

0.010

[− 0.194 to 0.214]

p = 0.920

0.114

[− 0.058 to 0.286]

p = 0.194

0.061

[− 0.140 to 0.263]

p = 0.551

0.162

[− 0.011 to 0.335]

p = 0.066

5 years

− 0.173

[− 0.212 to − 0.135]

p < 0.0001

− 0.155

[− 0.405 to 0.095]

p = 0.223

− 0.088

[− 0.300 to 0.124]

p = 0.414

0.018

[− 0.235 to 0.271]

p = 0.889

0.085

[− 0.130 to 0.300]

p = 0.437

0.103

[− 0.148 to 0.353]

p = 0.421

0.144

[− 0.075 to 0.363]

p = 0.196

PNT: participants not treated; PT < 75: participants treated less than 75% of the study follow-up; PT ≥ 75: participants treated more than 75% of the study follow-up.

(1)Adjustment for age, sex, body mass index (BMI), arterial hypertension, diabetes, allocation to MAPT intervention groups, baseline composite cognitive score and their interactions with time.